Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

Bone Marrow Transplantation

Volumn 44, Issue 2, 2009, Pages 81-87

  de Souza, J A ^a   Davis, M L ^a   Rondon, G ^a   Cheng, Y C ^b   Jones, R B ^a   Champlin, R E ^a   Ueno, N T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANASTROZOLE; ATOVAQUONE; CAPECITABINE; CARBOPLATIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUCONAZOLE; FLUOROURACIL; GEMCITABINE; LETROZOLE; MEPREDNISONE; METHOTREXATE; NAVELBINE; PACLITAXEL; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; TAMOXIFEN; TARIQUIDAR; TRASTUZUMAB; VALACICLOVIR;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE COURSE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG DISEASE; NEUROLOGIC DISEASE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SKIN DISEASE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NEOPLASM METASTASIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68149117281     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.101     Document Type: Article

References (22)

1. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620-623.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
3. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242-1243.
4. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
5. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
6. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB × NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984; 132: 997-1000.
7. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002; 30: 89-96.
8. Blaise D, Bay JO, Faucher C, Michallet M, Boiron J-M, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
9. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
10. Carella AM, Beltrami G, Lerma E, Cavaliere M, Corsetti MT. Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat Res 2002; 110: 101-112.
11. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
12. Schwartz DW, Glock B, Jungl EM, Mayr WR. Strategy to detect chimerism in allogeneic bone marrow transplant recipients by PCR-amplification fragment length polymorphism analysis of microsatellite polymorphisms. Vox Sang 1995; 68: 139-143.
13. Yam PY, Petz LD, Knowlton RG, Wallace RB, Stock AD, de Lange G et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399-407.
14. An International System for Human Cytogenetic Nomen-clature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects: Orig Artic Ser 1985; 21: 1-117.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
16. Imanguli MM, Childs RW. Hematopoietic stem cell transplantation for solid tumors. Update Cancer Ther 2006; 1: 343-352.
17. Oblon DJ, Paul S, Yankee R. Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE). Bone Marrow Transplant 1997; 20: 421-423.
18. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.
19. Carella AM, Bregni M. Current role of allogeneic stem cell transplantation in breast cancer. Ann Oncol 2007; 18: 1591-1593.
20. Carella AM, Ferrara R, Orcioni GF, Pepe G, Villavecchia G. Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting. Ann Oncol 2007; 18: 1751-1754.
21. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
22. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008; 41: 537-545.